Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Toshihiko Morikage"'
Autor:
Nagahiro Saijo, Yasuhiro Fujiwara, Yasutsuna Sasaki, Toshihiko Morikage, Terumi Takahashi, Kazuo Kasahara, Kazuto Nishio, Yoshikazu Sugimoto, Tohru Ohmori, Sei Ohta
Publikováno v:
Japanese Journal of Cancer Research : Gann
A cisplatin‐resistant non‐small cell lung cancer cell line, PC‐14/CDDP, was established from PC‐14 by stepwise escalation of CDDP concentrations in vitro. PC‐14/CDDP cells were 11.4‐fold more resistant to CDDP compared with PC‐14 cells.
Autor:
Nagahiro Saijo, Yuichiro Takeda, Naohiro Kubota, Toshihiko Morikage, Kaoru Abe, Kazuto Nishio, Tohru Ohmori, Keizaburo Miki, Yasuhiro Fujiwara
Publikováno v:
Japanese Journal of Cancer Research : Gann
A cyclic adenosine 3′,5′-monophosphate (cAMP) analogue, 8-chloro-cAMP (8-Cl-cAMP), had a collateral growth-inhibitory effect on a cis-diamminedichloroplatinum(II) (CDDP)-resistant human cancer cell lines (PC-14/CDDP). The non-selective analogues
Publikováno v:
Oncology. 48:431-437
We examined death rates in Fisher rats when chemotherapeutic drugs were administered in a prescribed amount by either a single or divided dose. Lower death rates were observed when nimustine hydrochloride (ACNU) was given in a divided dose, or when c
Publikováno v:
The Tohoku Journal of Experimental Medicine. 163:47-57
In order to make clear the characteristic biological properties of IL-1 alpha, its protective capabilities on bacteria-induced and LPS-induced lethality were compared with other BRMs in BALB/c mice. Pretreatment with IL-1 alpha (i.p., s.c.) or OK-432
Autor:
Akimi Takashima, Keiko Konishi, Saburo Yano, Toshihiko Morikage, Akira Kawasaki, Tatsuhiko Kashii, Hitoshi Hirata, Yutaka Mizushima, Kiyoshi Hoshino
Publikováno v:
Japanese Journal of Medicine. 29:146-155
A survey regarding the revelation of the diagnosis of cancer to patients was conducted on 116 medical doctors (MD), 206 paramedical personnel (PP) and 789 lay persons (LP) in June 1989 in Toyama prefecture, Japan. When asked in the case that their pa
Autor:
Kazuto Nishio, Nagahiro Saijo, Hisanobu Niitani, Tohru Ohmori, Yuichiro Takeda, Kaoru Miura, Naohiro Kubota, Shoji Kudoh, Toshihiko Morikage
Publikováno v:
International journal of cancer. 58(6)
Okadaic acid (OA), a specific protein phosphatase inhibitor, has various biological functions. To elucidate the mechanism of OA resistance, we have established a small-cell lung-cancer subline (H69/OA100) resistant to the growth-inhibitory effect of
Autor:
Tohru Ohmori, Sei Ohta, Yuichiro Takeda, Toshihiko Morikage, Nagahiro Saijo, Kazuto Nishio, Naohiro Kubota, Kazunaga Yazawa
Publikováno v:
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 203(2)
The effect of ascorbic acid 6-docosahexaenoate (DHA-VC) on the phospholipase-C-mediated hydrolysis of phosphatidylcholine was investigated. In human non-small cell lung cancer cells (PC-14) exposed to DHA-VC for 24 hr, a dose-dependent increase in ph
Autor:
Nagahiro Saijo, Yuichiro Ohe, Tohru Ohmori, Toshihiko Morikage, Yasuhiro Fujiwara, Yoshikazu Sugimoto, Kazuto Nishio
Publikováno v:
British Journal of Cancer
A cisplatin(CDDP)-resistant subline of a human lung cancer cell line, PC-7/CDDP, was 4.7-fold more resistant to CDDP than the parent line in a colony-forming assay. The sensitivity of this cell line to anthracyclines, vinca-alkaloid, etoposide, mitom
Autor:
Akira Kawasaki, Shoko Matsui, Akihito Yokoyama, Yutaka Mizushima, Toshihiko Morikage, Hiroshi Tsuji, Saburo Izumi, Saburo Yano, Yoshimasa Kin, Hitoshi Hirata
Publikováno v:
Tumori. 77(4)
To characterize basic fetoprotein (BFP) as a new tumor marker, we measured serum levels of BFP and 5 other tumor markers (CA19-9, CEA, NSE, SCC, and TPA) concomitantly in 65 patients with lung cancer, 57 patients with benign pulmonary disease, and 40
Autor:
Toshihiko Morikage, Tohru Ohmori, Masami Bungo, Mitsuji Yoshida, Yasuhiro Fujiwara, Nagahiro Saijo, Motoko Inomata, Kazuto Nishio
Publikováno v:
Japanese Journal of Cancer Research : Gann
The potentiation of anticancer agents by non-anticancer drugs is one of the possible strategies for overcoming cellular resistance to chemotherapy. In order to overcome cis-diamminedichloroplatinum-(II) (CDDP) resistance, we evaluated the sensitizing